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INTRODUCTION 
  
INTRODUCTION 
 
 Despite immense advances in intensive care medicine, surgical 
technique, and hygiene; nosocomial infections still represent a major 
clinical problem in modern-day surgery.1 According to a survey of 3,147 
patients admitted to a surgical intensive care unit, infection was identified 
in 37% of the patients causing 24% mortality.2 Another recent study has 
shown that in patients with post surgical sepsis, 85% had an intra-
abdominal source.3 Male gender, advanced age, presence of 
comorbidities, inadequate nutritional status, complications of  operations, 
shock, multisystem organ failure, high APACHE II-score, emergency 
procedures, and multiple procedures were among the most common risk 
factors for hospital acquire infections in surgical patients.2,3. 
 Pancreatic surgery is fraught with infectious complications. Inspite 
of standardized techniques atleast 10% of patients develop intra-
abdominal abscesses while another 10% experience wound infections.4 
These numbers exponentially increase, if other complications such as 
pancreatic leak or delayed gastric emptying  occur.4, 5  
 Even in the highest-volume centers, pancreatic resections are 
associated with a high overall morbidity, in the range of 35% to 60%.4,5 
These figures remain constant even in the large volume centres across 
continents.6,7 In a recent review, infections occurred in nearly one-third 
of patients. In patients undergoing proximal or distal pancreatic 
resections, infections occurred in nearly 30% of  cases and accounted for 
a 40% escalation in the total cost of the procedure along with a increased 
duration of hospital stay.6 Pancreatic fistula with a collection / abscess 
(28%), followed by wound infection (24%) accounted for the majority of 
infections.4,5,6 Other causes included pneumonia (17%), abscess (15%), 
urinary tract infection (10%), and sepsis (6%). Most of them started off 
with one infection and progressed to multiple infections. These are 
responsible for a significant financial, economic and emotional burden on 
patients, doctors, and healthcare system alike.3,4,6,7  
 These infections occur despite a strict adherence to infection 
control regulations, standardized surgical techniques, refinements in 
perioperative care, use of aggressive and appropriate evidence based 
perioperative antibiotic prophylaxis and potent antibiotics. 3,4,6,7 This 
emphasizes the necessity to find better process improvements to decrease 
infectious complications, a few of which include reevaluating the 
effectiveness of antimicrobial prophylaxis regimens and regular auditing. 
 Post-surgical morbidity due to septic manifestations is only partly 
attributed to the surgeon and the surgical technique. Increasing evidence 
suggests instead that it is the patient’s ability to resist disease/immune 
defense and especially supportive measures during and around the 
treatment, such as mechanical ventilation, use of implants, drains and 
intravascular lines, but also choice of content and routes to provide 
nutrition, blood transfusions, choice of anesthesia and prescription of 
drugs, also antibiotics and immunosuppressives, that are the largest 
contributors to the development of septic manifestations. 
 Mechanical ventilation in association with management of 
emergencies and surgical procedures has in recent years received 
increasing attention as a major contributor for not only chest-infections, 
but also for other general and localized septic manifestations in the body.8 
This treatment is responsible for, not only a disproportional amount of 
resources used, but also for the unacceptably high morbidity and mortality 
associated with the treatment, especially in elderly people.6 A main 
contributor to intensive care unit (ICU)-associated sepsis is also artificial 
nutrition, both enteral and parenteral; catheter-related sepsis is reported 
to occur in about 25% of patients fed via intravenous feeding-tubes.3,7  
 Numerous drugs used in the ICUs including antibiotics are known 
to derange the immune functions, impair macrophage functions, 
bactericidal efficacy as well as production and secretion of cytokines. 
Other common perioperative practices like use of artificial feeding 
regimens, preoperative antibiotics, and mechanical bowel preparation 
will also contribute to increased rates of treatment-associated infections 
 The intestinal lining is the first line of defense against bacteria, it 
isolates the systemic circulation from the bacteria. 8,9 The intestinal 
epithelium consists of a single layer of columnar cells starting at the 
gastroesophageal junction and extending to the squamous epithelium of 
the anal canal. This physical barrier is selectively permeable and capable 
of preventing transmigration of pathologic luminal substances from the 
external environment, that is, the lumen, to the internal environment.8,9 
The basal and apical portions of the cells are closely bound to one another 
with filaments, to maintain normal polarity and tight junctions.8,9,10,11 Cell 
turnover occurs in a systematic fashion approximately every 5 to 7 days 
under the control of various growth factors, including epidermal growth 
factor, intestinal trefoil factor etc. 8,9,10,11  
 This mucosal epithelial lining is covered by microproteins in the 
form of mucin, which coats the surface to create a physical barrier against 
the bacteria. Mucin contains high concentrations of antibacterial 
molecules such as defensins and others like  lactoferrin, lysozymes, and 
sPLA2.10,11,12,13 sPLA2 destroys the integrity of the bacterial cell wall, 
whereas lactoferrin impairs the ability of bacteria to adhere to epithelial 
cells. 8,9,10,11,12 Bacterial invasion occurs under conditions of  surgical 
stress along with alterations in normal oral intake and reductions in the 
mucin layer leading onto an impairment of the antimicrobial peptides in 
the mucin layer, and increased mucosal permeability weakening this 
intrinsic defense mechanism.13,14,15,16,17 This disruption of the gut barrier 
can result in systemic inflammation and septic complications. 12,13 
Disruption of gut barrier function and intestinal microbial imbalance can 
result in systemic inflammation and ultimately induce septic 
complications after surgery.6,7,12 
 The true size and diversity of the human microbiota is largely 
unfathomed.14,15 The application of modern technologies—genomics, 
metagenomics, and metabolomics—to the study of the colonic microbiota 
has the potential to expose the true diversity and metabolic profile of the 
microbiota and the reveal the real extent of changes which occur in a 
diseased state.16,17,18,19,20,21 Techniques based on 16S rDNA sequences 
have revealed that the diversity of the human microbiota is far greater 
than previously assumed and that most bacterial sequences are 
unculturable sequences and novel bacteria.18,19 Metagenomics indicate 
that the human gut houses somewhere to the order of 30,000 to 40,000 
different microorganisms, and their physiological roles organisms  are yet 
to be discovered.16,17   
 The human bowel houses about 1014 viable microorganisms, which 
constitute 95% of the cells in our bodies, the size of their population 
exceeds the total number of somatic and germ cells in our body.12,16 Most 
of the bacteria are located in the colon. 12,17 The so-called indigenous gut 
microbiota has several important functions which include prevention of 
colonization by pathogenic organisms, modulation of local and systemic 
immunity, feeding of enterocytes, and maintenance of intestinal motility 
and mucus secretion to just name a few. 11,12,13,14,16,17  
 The gut microbiota or microflora has a crucial role in human health 
and disease. The GIT is comprised of the entire digestive system from the 
stomach to the anus. The colon is the organ which is the preferred site for 
bacterial colonization. The GIT is also rich in many molecules which can 
be used as nutrients by microbes.  The mucosa of the gastrointestinal tract 
is continuously exposed to an environment that is rich in foreign 
substances, such as food particles and antigens of microbial origin.2,4,8 
Particular changes in the intestinal ecosystem might contribute to the 
development of certain illness. There is therefore a need for an exhaustive 
review on the functions of the gut microbiota, occurrence of gut dysbiosis 
(alteration or imbalance of the microflora), how these intestinal bacteria 
trigger development of disease once the normal flora of a healthy 
individual is imbalanced, exploiting this intricate and interwoven 
ecosystem for understanding human health, development of 
biotherapeutics, and future perspectives.3,8,9,10 
 The composition of this gut bionome is not the same across the 
length of the gut, it demonstrates variation along its diameter, with certain 
bacteria tending to be adherent to the mucosal surface while others 
predominate in the lumen. 18,19,20 The composition of the microbiota is 
also influenced by age, diet, socioeconomic conditions and the use of 
antibiotics. These bacteria help to the shape individual human physiology 
by influencing the expression of genes critical to the proper development 
of intestines and their function, including nutrient absorption and 
metabolism, metabolism of toxins, gut maturation, and 
angiogenesis.14,16,17,18  
 The process by which intraluminal bacteria transgress the intestinal 
mucosa to reach the local lymph nodes is called bacterial translocation.  
This translocation by potentially pathogenic bacteria has been associated 
with an increased incidence of postoperative sepsis. Bacterial 
translocation after pancreatic surgery has been reported to occur in 20% 
of mesenteric lymph nodes, and these patients commonly experience 
infections and complications.12,13 
 Patients undergoing surgery have several risk factors for 
disturbance of the intestinal microflora, resulting in translocation from 
pathogenic bacteria into mesenteric lymph nodes, blood, and other 
organs. 14,16,17,18 Decreased postoperative intestinal motility, jaundice, 
antibiotics usage, loss of mucosal barrier function due to malnutrition, 
manipulation of the bowel, parenteral nutrition,  suppression of the 
immune system by blood products and operative trauma are all factors 
which promote this translocation.12,13,14,16,17  
 A certain degree of bacterial translocation is physiological and has 
been shown to occur after sham operations. 14 Severe bacterial overgrowth 
and subsequent translocation results in bacterial infections or even sepsis. 
13,14,16
 The majority of these observed infections are caused by bacteria 
from the gut, especially Enterococci and Escherichia coli, which 
translocate into mesenteric lymph nodes or into the blood. In study 
analyzing the microbiology of subphrenic abscesses, aerobic bacteria 
were cultivated in 13%, anaerobic bacteria in 21%, and a mixed flora in 
65%, with clear predominance of Escherichia coli, Enterococci, 
Staphylococcus aureus, and Bacteroides fragilis.4,13,17,18,19,20 Bacterial 
smears in patients with postoperative peritonitis in 355 patients showed 
E. coli in 51%, Enterococci in 30% and B. fragilis in 25%.4 
 There are three general methods by which the intestinal microflora 
can be altered: administration of antibiotics, prebiotics (i.e., dietary 
components that promote the growth and metabolic activity of beneficial 
bacteria), probiotics (i.e., beneficial bacteria), or fecal transplant 
(bacteriotherapy). Combination of these methods is also possible 
(synbiotics). Interest in these approaches has extended well beyond the 
clinical sciences since a role for intestinal microbes in health and disease 
has been recognized in alternative and complementary forms of medicine 
for many years 
 Fecal microbiota transplantation (FMT) is the process of 
transplantation of fecal bacteria from a healthy individual into a recipient. 
It has been proven to be a highly effective treatment for patients suffering 
from C.Difficile induced pseudomembraneous colitis.18,19 Previous terms 
for the procedure include fecal bacteriotherapy, fecal transfusion, fecal 
transplant, stool transplant, fecal enema and human probiotic infusion 
(HPI). The procedure involves the complete restoration of the entire fecal 
microbiota, by introducing healthy bacterial flora through infusion of 
stool, e.g. by enema, obtained from a healthy human donor.19 Infusion of 
feces from healthy donors was demonstrated in a randomized, controlled 
trial to be highly effective in treating recurrent C. difficile, and more 
effective than vancomycin alone.21 It can also be used to treat other 
conditions, including colitis, constipation and irritable bowel 
syndrome and some neurological conditions. A modified form of fecal 
bacteriotherapy (Autologous Restoration of Gastrointestinal Flora - 
ARGF) which involves an autologous fecal sample, provided by the 
patient before medical treatment, stored in a refrigerator.16,18 Should the 
patient subsequently develop C. difficile, the sample is extracted with 
saline and filtered. The filtrate is freeze-dried and the resulting solid 
enclosed in enteric-coated capsules.  
 It was once considered to be "last resort therapy" due to its unusual 
nature and 'invasiveness' compared with antibiotics. Due to the 
psychological barrier along with a perceived potential risk of infection 
transmission, the recent position statement by specialists in infectious 
diseases and other societies is divided as to its indications in mainstream 
gastroenterology. Probiotics are able to partially provide the beneficial 
microbiological milieu, as offered by FMT. 18,19,20 
 Probiotics were first described by Metchnikoff in 1908 based on 
his observations on the longevity of individuals who lived in a certain part 
of Bulgaria and which he attributed to their ingestion, on a regular basis, 
of a fermented milk product. Probiotics are defined by the Food and 
Agriculture Organization of the United Nations and the World Health 
Organization (WHO) as live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host.22 Tremendous 
interest has developed in ways the ecosystem of the gut may be altered, 
not only to decrease pathogenic numbers but also to promote overall 
health. Many different foods and supplements that contain microbes—
namely, species of bacteria or yeasts—have been used.22,23 These 
products are widely known as probiotics, a hybrid word created by 
combining the Latin pro- (“for”) with the Greek adjective -biotic (“life”). 
22
 Probiotic is a preparation or product containing a defined single or 
mixed culture of live microbes that, when ingested in sufficient numbers, 
will exert beneficial effects on health beyond basic nutrition by altering 
the gastrointestinal microbiota. 22 
 For a food or supplement to be considered as a probiotic, it must 
meet several criteria. It must contain live organisms capable of colonizing 
the gastrointestinal tract, implying these organisms need to be acid and 
bile tolerant. It should improve the health and well-being of the host. They 
should be generally recognized as safe (GRAS) and non pathogenic. 
Host-specific strains of organisms should be used; humans should receive 
strains specific to humans and not of animals.22  
 Thirty to forty species account for 99% of the bacteria present in 
the human gut and these species are selected to be used therapeutically. 
The two most common genera of bacteria used as probiotics are 
Bifidobacterium (e.g., Bifidobacterium bifidus) and Lactobacillus (e.g., 
Lactobacillus reuteri). Strains of Streptococcus and Enterobacteriaceae 
are less commonly included. Saccharomyces boulardii, a probiotic yeast, 
has been found to have a wide array of benefits and is gaining popularity. 
Products may contain just one species, or they may contain a mixture of 
different organisms.22,23,24 
 Probiotics differ in their ability to resist gastric acid and bile acids, 
colonize the intestinal tract, and influence cytokines secreted by intestinal 
epithelial cells.22,23 Thus, not all probiotics are alike; as a result, benefits 
observed clinically with one species or with a combination of species are 
not necessarily generalizable to another. Although yogurt is commonly 
recommended as a source of probiotics, not all of the live cultures 
contained in yogurt survive well in an acidic environment nor do they 
colonize the microbiota efficiently. 
 The science of probiotics is imperfect, with many of its lacunae 
being scrutinized carefully by investigators world over. In general, 
demonstrating the colonization of the supplemented probiotic 
microorganisms has been the primary aim of most studies in healthy 
individuals. In most cases, a transient colonization of the probiotic 
microorganisms has been observed. It is still questionable, however, 
whether probiotic strains would need to colonise in order to be effective 
or whether transient presence would also suffice to exert health-beneficial 
effects.26  
 Administration of a given probiotic strain will result in the 
temporary increase of that strain the GI tract, but may also change the 
overall composition of the intestinal microbiota. Which probiotic 
microorganisms are able to influence the relative abundance of which 
specific intestinal microorganisms are questions that are currently under 
study. It is also imperative to realize that a change in composition or 
diversity of the intestinal microbiota by probiotic intervention is not a 
health benefit by itself.24,27 The effects of probiotics on the intestinal 
microbiota composition in healthy individuals are even more difficult to 
interpret. Studies do provide information on the effects of probiotics on 
the intestinal microbiota without a potential bias caused by disease 
effects. However, this does not imply that in a diseased situation these 
probiotic products will have the same influence on the intestinal 
microbiota. 
 Probiotic studies performed in humans have almost exclusively 
examined the effect of probiotic administration on the composition of the 
faecal microbiota, whereas other niches of the GI tract have hardly been 
studied thus far. This means that there is still a major gap in knowledge 
on the influence of probiotic microorganisms on the intestinal 
microbiota.26,27,28 There is a lack of standardised methods for the study of 
the intestinal microbiota (e.g. sample collection, sample storage and 
analysis methods), which makes it almost impossible to directly compare 
findings from different groups. Apart from the large variety of probiotic 
species and strains, different dosages of probiotic; the diverse populations 
of interest can be relatively heterogeneous since health and disease are 
not always well defined.  All of this, in combination with the fact that the 
intestinal microbiota composition is diverse and maybe even unique for 
each individual, makes it problematic to observe general changes in 
microbiota composition as result of probiotic intervention.29 
 Different strains differ with regard to their ability to colonise and 
proliferate in the GI tract. Approximately 1-10% of L. acidophilus 
ingested in fermented product were found to survive until the ileum in 
several human studies using intestinal intubation techniques.19,20,27,29 To 
be effective probiotic cultures must be able to withstand processing 
conditions, retain their probiotic properties after processing and survive 
in sufficient numbers in the product during shelf-life storage. The stability 
of a probiotic is linked to various factors, including genus, species, strain 
biotype and, above all, the formulation storage conditions.26,30,31 
 The faecal recovery of bifidobacteria and lactobacilli in healthy 
subjects exhibited a dose response relationship. A 10-fold increase of 
ingested bacteria caused the average number of recovered viable strain to 
increase by a factor of 20.32 Hence the higher the ingested dose, the 
greater the number of subjects positive for viable bacteria. The suggested 
minimum viable number is 106 CFU/ml or gram, with a recommended 
dose of 108 CFU/g to compensate for reduction through passage through 
the gut. It is accepted that at the point of consumption probiotic products 
should have a minimum concentration of >1 x 106 CFU/ml or gram and 
that a total of some 108 to 109 probiotic microorganisms should be 
consumed daily if therapeutic effects are to be realised.18,19,22,24,25,32 
 The fundamental mechanisms of action of probiotics, include, 
blockade of toxin receptor sites, inhibition of the growth of pathogenic 
microbes, inhibition of receptor site attachment by pathogens, 
engagement in cross-talk with other flora thereby enhancing resistance to 
colonization, enhancement of tight junction bonding and prevention of 
impaired barrier function, production of cytochrome P-450–like enzymes 
and facilitation of detoxification, exertion of trophic effects by 
influencing transport pathways and the production of energy and protein, 
as well as by releasing enzymes that facilitate the maturation of 
enterocytes.25,26,27,28,29,30,31 They also produce B vitamins and vitamin K. 
Probiotics interact with the immune system and lead to an alteration in 
secretory immunoglobulin A levels, decrease the  inflammatory effects of 
natural killer cells, and trapping helper T cells in mesenteric lymph nodes 
to decrease the inflammatory response.30,31,32,33,34  
 These organisms create a physiologically challenging environment 
(low pH, production of toxic byproducts), by leading to competitive 
consumption of nutrients, reduction of concentrations of oncogenic 
enzymes in the gut and by direct DNA signaling.35,36  
 Even dead probiotic organisms can exert an influence on certain 
aspects of gut physiology; a phenomenon referred to as the probiotic 
paradox.37 Secreted proteins and DNA of one probiotic preparation 
blocked cytokine activation and prevented apoptosis of epithelial cells. 
The effects depended upon the specific DNA from the different bacterial 
species that were components of the preparation, and not on the live 
probiotic itself. Non-methylated DNA from randomly selected E. coli 
strains suppressed experimental colitis in several animal models.24,26  
These therapeutic effects are mediated through toll-like receptor 9 and 
with induction of type 1 interferons alpha/beta.27  Defined molecular 
weight proteins from other probiotic species, including Lactobacillus GG, 
can also inhibit proinflammatory signaling and inflammatory cytokine-
induced apoptosis in colonic epithelial cells through an epidermal growth 
factor receptor (EGFR)-dependent mechanism, while secreted products 
from a variety of species can inhibit cytokine production.23,27 
 Direct effects include prevention of bacterial overgrowth by 
secretion of antimicrobial bacteriocines and competitive growth, 
induction of colonization resistance against pathogenic bacteria by 
competitive blocking of bacterial adhesion and invasion of epithelial 
cells, upregulation of intestinal mucus production, and secretion of 
antimicrobial peptides like beta-defensin 2.38,39,40 Furthermore, they help 
in maintaining epithelial integrity through feeding of enterocytes, 
production of omega-3-fatty acids, inhibition of pathogenic-induced 
alterations of epithelial permeability and regulation of enterocyte gene 
expression.39,40,41  
 Indirectly, some strains are able to specifically stimulate the innate 
and systemic immune system. 41,42 Probiotics have been shown to 
modulate the human dendritic cell phenotype and function, to reduce pro-
inflammatory cytokines and to induce anti-inflammatory cytokines like 
IL-10, to stimulate nonspecific resistance to microbial pathogens by 
activation of macrophages and to increase systemic and mucosal IgA 
responses.37,39,40 The relationship between the host’s immune system and 
nonpathogenic constituents of the microbiota is important in protecting 
the host from colonization by pathogenic species.42  
 The gut bacteria are known to produce a large number of vitamins 
like the B group of vitamins, synthesize amino acids, and carry out 
biotransformation of the bile. Biotransformation of bile by microbial 
enzymes is important for the metabolism of glucose and cholesterol. 
33,34,36 
 Importantly, the microbiome  provides the much needed 
biochemical pathways for the fermentation of nondigestible substrates 
like fibers and endogenous mucus. Fermentation or metabolism of these 
nondigestible substrates lead to the growth of these microbes and the 
production of short chain fatty acids and gases. 33,34   
 The major short-chain fatty acids produced are acetate, propionate, 
and butyrate. Other bacterial end products include lactate, ethanol, 
succinate, formate, valerate, caproate, isobutyrate, 2-methyl-butyrate, and 
isovalerate.33,36,37 Bacterial fermentation takes place in the cecum and 
colon, where the short-chain fatty acids are absorbed, stimulating the 
absorption of salts and water. These short-chain fatty acids have a 
protective effect on the intestinal epithelium. 33,39,42 The colonic bacteria 
prefer butyrate as the sole source of energy, and most of it is completely 
metabolized. The principal short chain fatty acid produced in the colon is 
acetate, and  it serves as a substrate for biosynthesis of cholesterol. Thus, 
the gut microbiota performs various metabolic acitivities which are 
essential for the host’s metabolism 
 Prebiotics are nondigestable food constituents that selectively alter 
growth or activity of one or a limited number of bacterial species in the 
colon in a manner that potentially improves and promotes the health of 
the host.22 Prebiotics reach the colon untouched and serve as colonic food 
that will be converted by probiotics to important nutrients.22,24,26,27 They 
are selectively fermented ingredients that stimulate specific changes in 
the colonic microbiota which benefit the health of the host.30,31,32  
 While probiotics introduce exogenous bacteria into the human 
colon, prebiotics stimulate the preferential growth of a limited number of 
health-promoting species already residing in the colon, especially 
lactobacilli and bifidobacteria.38,40 The prototypical prebiotics are the 
oligosaccharides in human breast milk which facilitate the preferential 
growth of bifidobacteria and lactobacilli, in the colon, among exclusively 
breast-fed neonates; this phenomenon accounts for the immunologic and 
other benefits that accrue to breast-fed infants.39,40,41  
 The notable prebiotics are the inulin-type fructans, which are 
linked by β (2–1) bonds that limit their digestion by upper intestinal 
enzymes, and fructo-oligosaccharides.29,30,32 They are present in 
significant amounts in many edible fruits and vegetables, including 
wheat, onion, chicory, garlic, leeks, artichokes, and bananas. Inulin and 
oligofructose stimulate the growth of bifidobacteria at the expense of 
Bacteroides, Clostridium, and coliform bacteria.31,33,34 Chicory fructans 
have also been shown to enhance the absorption and balance of dietary 
calcium.34,35  
 Other oligosaccharides, such as xylose, maltose, and mannose, also 
show promise as prebiotics. Because of their chemical structure, 
prebiotics are not absorbed in the small intestine but are fermented, in the 
colon, by endogenous bacteria to energy and metabolic substrates, with 
lactic and short-chain carboxylic acids as end products of the 
fermentation.33,34,41,42  
 Used in combination, probiotics and prebiotics are called 
synbiotics.41 They are designed to have synergistic or additive effects 
benefiting the host.  The thinking is that consuming both at once, instead 
of just the probiotic alone, may enhance microbe survival during transit 
through the upper gastrointestinal tract and lead to greater positive effects 
on the beneficial microbes already established in the intestines.41,42,43  
 Synbiotics have demonstrated beneficial effects with respect to the 
function of innate immunity, intestinal barrier function, and increased 
resistance to disease. The gut mucosa and microbiota are intimately 
linked in the maintenance of a functional interface between the host and 
the external environment.6,39,40  
 Synbiotics have synergistic effects in enhancing immunity and 
facilitating intestinal barrier function. The term “defense by diversity” 
was coined in 1999 to reflect the nature of synbiotic treatment.19 A recent 
review suggests that multispecies probiotics may be superior to single-
species probiotics in reducing antibiotic-associated diarrhea, preventing 
infections, and reducing pathogenic colonization. 28 
 Synbiotics have been found to decrease levels of proinflammatory 
cytokines, and hence found to be effective in improving clinical 
symptoms of active Crohn's disease.26 In addition, synbiotics containing 
Lactobacillus helveticus, Bifidobacterium infantis and Bifidobacterium 
bifidum, and fructooligosaccharide have been found to limit common 
winter infections in schoolchildren.27,28,29 
 
 Hypercholesterolemia, or elevated levels of total cholesterol in the 
bloodstream, is the result of high levels of low-density lipoprotein (LDL) 
as compared to high-density lipoprotein (HDL) cholesterol.33,39,40 Many 
Lactobacilli, being the natural inhabitants of the intestine, possess bile-
salt hydrolase activity. This property has been used for developing 
probiotic formulations to combat hypercholesterolemia. 
 Of 15 available Cochrane reviews on probiotics, 10 of these review 
focus on luminal gastrointestinal conditions or infections, including 
infectious diarrhea, antibiotic-associated diarrhea, C. difficile colitis, 
inflammatory bowel diseases (including pouchitis), necrotizing 
enterocolitis in preterm infants, collagenous colitis, and irritable bowel 
syndrome.24,25,26,27 Among these conditions, probiotics may reduce the 
risk of severe necrotizing enterocolitis in preterm infants weighing more 
than 1000 g; it also has utility in the maintenance of chronic pouchitis 
remission status post pouch-anal anastomosis.25,28,29 Probiotics have also 
been found to be a useful adjunct to oral rehydration therapy for infectious 
diarrhea.30 However, a more recent meta-analysis evaluating the use of 
probiotics in acute, likely infectious, diarrhea noted that the majority of 
the data was derived from hospital-associated studies, with a paucity of 
community-based trials of probiotic use in acute diarrhea and only one 
trial available from a developing world setting..37,38  
 Cochrane reviews of probiotic studies in antibiotic-associated 
diarrhea, C. difficile colitis, collagenous colitis, and irritable bowel 
syndrome reported either no evidence of probiotic effectiveness in these 
conditions, or the available data were deemed insufficient to allow clear 
conclusions regarding efficacy.31,32,33  Although various probiotic species 
have shown promise in the treatment of inflammatory bowel disease, 
given the small number of patients, differences in study durations and 
heterogeneity  in these studies and the risks associated with probiotics, 
two systematic reviews have concluded that there is insufficient evidence 
to support the use of probiotics for the induction or maintenance of 
remission in inflammatory bowel disease. 32,33 
 Prebiotic and probiotic therapy appear to lower blood ammonia 
concentrations, possibly by favoring colonization with acid-resistant, 
non-urease producing bacteria.28,29,30 The most commonly used prebiotic 
for the treatment of hepatic encephalopathy is lactulose, though it also 
acts by altering the colonic pH, improving gastrointestinal transit, and 
increasing fecal nitrogen excretion.29 Fermentable fiber is another 
prebiotic that may promote the growth of beneficial bacteria. Initial 
studies were associated with an improvement in hepatic encephalopathy. 
However, a large meta-analysis has shown no demonstrable benefit with 
regard to clinically relevant outcomes (e.g., mortality and quality of life). 
31
 
 Two Cochrane reviews which addressed the role of probiotics in 
the prevention of allergic disease and food hypersensitivity in infants and 
the treatment of eczema, concluding that the probiotics studied were 
either ineffective or there was insufficient evidence to recommend 
probiotic use at present in these conditions.34,36,37 The remaining three 
Cochrane reviews evaluated probiotic use in the prevention of bacterial 
sepsis and wound complications in liver transplantation, treatment of 
nonalcoholic fatty liver disease, and prevention of preterm labor and 
concluded that the available data were similarly inconclusive.41,42,43 
 Pro-/pre-/synbiotics’ potential anticancer activity has been mainly 
supported by a number of laboratory studies.38,40 Alteration of the 
intestinal microflora composition/competition with the consumption of 
probiotics, reduction of intestinal inflammation (as well as of the 
mutagenic, carcinogenic and genotoxic compounds), elevation of 
immune response and increased short-chain fatty acid production have 
been proposed as potential chemopreventive mechanisms.48,61 
 A metagenomic analysis of 154 individuals, including 
monozygotic and dizygotic twins concordant for leanness or obesity, and 
their mothers also showed that obesity was associated with a relative 
depletion of Bacteroidetes and a higher proportion of Actinobacteria 
compared with leanness.38,40,41,51 Consistently, one prospective study 
found that children with lower proportion of Bifidobacterium and higher 
levels of Staphylococcus aureus in their infancy gained significantly more 
weight at 7 years.43,44 
 Changes in energy harvesting from diet is also associated with the 
uptake of SCFAs, end products of bacterial fermentation: in obese 
humans, the amount of SCFAs in fecal samples was greater than in lean 
subjects, although the diets rich in nondigestible fibers decrease body 
weight and severity of diabetes; these contradictory findings could be 
explained by the anti-inflammatory effects of butyrate.44,48,49 
Furthermore, another pathway has been better studied in humans: the 
linkage between microbiota and systemic inflammation. LPS 
administration induces acute inflammation and systemic insulin 
resistance, stimulating the systemic and adipose tissue expression of 
proinflammatory and insulin resistance-inducing cytokines.46  
 Consistently in healthy human subjects, total energy intake and 
high-fat / high carbohydrate meals, but not fruit / fiber meals, can acutely 
increased plasma LPS levels, coupled with enhanced TLR4 
expression.22,46  The different pathophysiologic factors that explain the 
association of microbiota with metabolic disturbances have not been 
studied in depth in human in comparison with animal models, although 
growing evidences link gut microbiota with endotoxemia and energy 
harvest from diet 
 Several prebiotic and probiotic preparations have shown promise 
in preventing or treating various conditions. However, most studies have 
been small and many have important methodological limitations, making 
it difficult to make unequivocal conclusions regarding efficacy, especially 
when compared with proven therapies. Furthermore, considerable 
differences exist in composition, doses, and biologic activity between 
various commercial preparations, so that results with one preparation 
cannot be applied to all probiotic preparations. 
 The appropriate therapeutic route, length of therapy, time of 
administration, and dosage of the probiotics and/ or synbiotics remain 
controversial issues 
 Probiotics, particularly lactobacilli, lactococci, and Bifidobac-
terium, are thought to be generally safe based on a long history of 
extensive use with likely daily ingestion by millions of individuals and 
limited reports of toxicity.  Certain probiotic products have been studied 
in at-risk populations without reported toxicity or adverse outcomes. 
However, in general, there is insufficient information on most marketed 
probiotic preparations to provide assurances regarding safety.37,39,40 
 Although population-based studies appear reassuring about the 
toxicity of probiotic use, other data raise concerns about the use of at least 
certain probiotics in vulnerable patient populations, particularly 
immunocompromised hosts, the severely ill, those with serious 
comorbidities, patients with intravenous catheters, prosthetic material or 
hardware, short bowel syndrome, or abnormal cardiac valves, and the 
elderly.21,22,38,42 In particular, a recent randomized, double-blind, placebo-
controlled trial designed to evaluate the effectiveness of a probiotic 
preparation (6 different Lactobacillus or Bifidobacterium strains; total 
daily dose 1010 bacteria) on infectious complications of acute pancreatitis 
reported increased mortality in the probiotic treatment group without any 
measurable impact on infectious complications.42,43  
 Further, bowel ischemia was significantly increased in the patients 
with acute pancreatitis treated with the probiotic. Bacteremia, 
endocarditis, and liver abscess have been reported as due to Lactobacillus 
spp. infection (including L. rhamnosus GG), with enhanced concern in 
individuals with short gut syndrome, central venous catheters, intestinal 
feeding tubes, or serious comorbidities.38,39 Similarly, although 
Saccharomyces boulardii (brewer’s yeast) is an infrequent fungal 
bloodstream isolate, in one series 86% of S. boulardii fungemia episodes 
were identified in children or adults who ingested S. boulardii as a 
probiotic.31,33 Mortality or sepsis with shock has been reported as due to 
invasive  infections associated with probiotic use. Other concerns about 
probiotic use, such as precipitating lactic acidosis, toxicity to the gastro-
intestinal tract, and transfer of antibiotic resistance within the 
gastrointestinal tract, remain theoretical in the absence of substantiation 
in clinical studies or reports.38,40,41,42,43 
 Since probiotics contain live microorganisms, concurrent 
administration of antibiotics could kill a large number of the organisms, 
reducing the efficacy of the Lactobacillus and Bifidobacterium species. 
Patients should be instructed to separate the administration of antibiotics 
from these bacteria- derived probiotics by at least two hours. 41,42 
Similarly, S. boulardii might interact with antifungals, reducing the 
efficacy of this probiotic.28 Probiotics should also be used cautiously in 
patients taking immunosuppressants, such as cyclosporine, tacrolimus, 
azathioprine, and chemotherapeutic agents, since probiotics could cause 
an infection or pathogenic colonization in immunocompromised patients 
23,27,28,29
 
 Warfarin acts by blocking the intracellular activation of vitamin K. 
Intestinal bacteria produce a significant proportion of the vitamin K 
absorbed in the intestine locally, while antibiotics causing the disruption 
of the intestinal flora has been associated with symptomatic K vitamin 
deficiency and severe hemorrhage. 33,34,37,38 It is therefore conceivable that 
administration of bacteria that alter the local production of vitamin K 
could affect the sensitivity to warfarin and other vitamin K antagonists 
 While synbiotic combinations are considered to have beneficial 
effects on human health and medical conditions, their clinical value in 
surgical patients remains unclear given a paucity of applicable clinical 
studies.  In a first ever surgical study on probiotics from South Asia, we 
attempt to assess the clinical usefulness of synbiotics in patients who 
undergo surgery for chronic pancreatitis. 
  
  
 
 
 
 
 
AIM OF THE STUDY 
  
AIM 
 The objective of the present investigation is to determine the impact 
of perioperative synbiotic therapy on  
• postoperative infectious complications,  
• first bowel movement,  
• days in intensive care unit,  
• length of hospital stay 
• duration of antibiotic therapy  
• mortality 
in patients undergoing Frey procedure for Chronic Pancreatitis 
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 There are 15 randomized, controlled clinical trials assessing the 
role of synbiotics in surgical patients which have been published so far. 
Mixed abdominal surgery/colorectal surgery  
 Of the three studies which have been published, none have shown 
a significant positive effect of synbiotics in postoperative outcomes.44,45,46 
All three studies were performed by the same group. In the first study, 64 
patients received pre- and postoperatively 107 Lactobacillus plantarum 
299v plus oat fiber (Proviva, Skanemejerier, Malmö, Sweden). Compared 
to a placebo group (n= 65), there were no significant differences in the 
infection rates (13% versus 15%) and degree of bacterial translocation 
into mesenteric lymph nodes (12% versus 12%).  
 The second series included 72 patients who were perioperatively 
administered a synbiotic combination containing Lactobacillus 
acidophilus La5, Bifidobacterium lactis Bb-12, Streptococcus 
thermophilus, L. bulgaricus (Trevis, Christen Hansen, Denmark), and 
oligofructose, no significant differences were demonstrated with regards 
to infectious complications (32% versus 31%) and bacterial translocation 
(12%versus 11%). In the third study, 88 patients planned for colorectal 
surgery either received mechanical bowel preparation (MBP) alone, 
neomycin plus MBP, neomycin plus MBP plus synbiotics, or neomycin 
plus synbiotics.47  
 The combination of MBP, neomycin, and synbiotics significantly 
reduced bacterial translocation (21%, 5%, 0%, and 18% respectively) and 
the amount of fecal Enterobacteriaceae, but this was not associated with 
a  reduction in serum levels of CRP and IL-6 or septic morbidity (21%, 
18%, 15%, and 14% respectively). The lack of effectiveness of synbiotics 
could be explained by the relatively short postoperative period of 
administration (median time 4 days), the route of administration with 
doubtful survival of the probiotics in the stomach, and the inhomogeneous 
distribution of operations with low-risk operations (simple colectomies) 
resulting in low overall rates of bacterial translocation and infections.  
 Rayes et al performed their study with synbiotics in mixed cohort 
of surgical patients (colectomies, resections of liver, stomach, and 
pancreas). Early enteral nutrition with nasojejunal administration of one 
probiotic (L. plantarum 299) and inulin as fiber was compared with 
enteral nutrition plus inulin alone or parenteral nutrition alone. Thirty 
percent in the parenteral group developed infections compared to 10% in 
the other two groups. Due to the inhomogeneous nature of the group, there 
was an unequal distribution of Operations with different risk rates.48 The 
duration of administration was also very short (5days). Also, the results 
could have been influenced by the mode of nutrition, since bacterial 
infection rates in both groups with enteral nutrition were lower than in the 
group with parenteral nutrition. However, a subgroup analysis of patients 
who underwent Whipple’s procedure showed that these patients had the 
marked drop in infection rates from 50% to 14% in the group which was 
administered probiotics. 
Pancreas resection 
 Studies show that infections rates among patients undergoing 
major pancreatic resections are 46-57%.4,49,50,51 In a study from India, the 
infection rates were upto 60%.5 These subset of patients have multiple 
risk factors for translocation and infection. Nomura et al. studied 64 
patients scheduled for pancreaticoduodenectomy.52 Of the 64 patients 
studied by Nomura et al, 30 received a probiotic mixture of Enterococcus 
faecalis T-110, Clostridium butyricum TO-A, and Bacillus mesentericus 
TO-A. There was a significant reduction of infectious complications 
(23% versus 53%), the median length of hospital stay was found to be 
significantly lower (19 days versus 24 days) and there was also a 
reduction in the percentage of patients who developed delayed gastric 
emptying (10% versus 20%). In another study from Berlin, 80 patients 
undergoing a pylorus preserving pancreatoduodenectomy (PPPD) were 
randomized to receive early enteral nutrition via nasojejunal route; 40 
patients received a synbiotic cocktail of 1010 L. plantarum 2362, 
Lactobacillus paracasei subspecies paracasei F19, Leuconostoc 
mesenteroides 77:1, and Pediococcus pentosaceus 5-33:3 plus 
betaglucan, resistant starch, inulin, and pectin (Synbiotic 2000, 
Medipharm, Kagerod, Sweden). In the group receiving synbiotics, the 
incidence of nosocomial bacterial infections was significantly lower 
(12.5% versus 40%), and only mild wound and urinary tract infections 
occurred.49 
Acute pancreatitis 
 In a study from Hungary, forty-five patients with acute pancreatitis 
divided into two groups. One group received L. plantarum 299 plus oat 
fiber, while the other group received oat fiber plus heat-inactivated L. 
plantarum 299. There was a marked reduction in the number of patients 
who developed infected pancreatic necrosis, in the synbiotic group. 53,54. 
In another study by the same group, Synbiotics with only fibers was 
administered to 62 patients with acute pancreatitis. The incidence of 
systemic inflammatory response syndrome and multiorgan failure (MOF) 
was significantly lower in the synbiotic group (8 versus 14 patients). 53,54 
Even though not statistically significant, there was a lower incidence of 
MOF, septic complications, and mortality.  
 The first and, to date, the only surgical trial with serious adverse 
events of synbiotics was recently published by a Dutch group.55 In a 
multicenter, double-blind, placebo-controlled trial, by the Dutch 
Pancreatitis group,  296 patients with predicted severe acute pancreatitis 
either received a synbiotic preparation consisting of 1010 L. acidophilus, 
L. casei, Lactobacillus salivarius, Lactococcus lactis, Bifidobacterium 
bifidum, B. lactis plus cornstarch and maltodextrins (Ecologic 641, 
Winclove Bio Industries, Amsterdam, Netherlands) or placebo for 28 
days together with fiber-enriched enteral nutrition. Even though the rates 
of infectious complications were comparable in both groups (30% versus 
28%), the mortality rate was higher in the synbiotic group (16% versus 
6%).  
 The main cause of death was bowel ischemia (eight patients). One 
likely explanation for these results is the fact that more patients in the 
synbiotic group had organ failures before or during the day of the first 
dose of treatment. (13.2% versus 4.9%). In addition, mortality rates in 
patients with severe acute pancreatitis are generally very high regardless 
of the type of treatment. An association between bowel ischemia and the 
synbiotic combination has been proposed as one of the causative 
factors.51,55 Enteral feeding using high amounts of a fiber-enriched 
formula plus probiotics may lead to an increase in the intestinal oxygen 
consumption and ischemia in patients with organ failure, consecutive low 
blood pressure, and splanchnic hypoperfusion.  
Liver resection 
 Upto 30% of patients undergoing liver resection, develop bacterial 
infections and 10% intraabdominal  sepsis usually caused by enterogenic 
bacteria;56 The incidence of infections rises markedly after extended 
resections(45%). 57  In cases where bacteremia is present, the risk of liver 
failure rises to over 50% with a mortality of 40%. Limited hepatic 
clearance of lipopolysaccharides, excessive cytokine production of the 
liver, reduction of the function of the reticuloendothelial system, bile 
production, intestinal blood flow, and bowel motility are the reasons for 
bacterial translocation and infection.57,58 
 A study from Japan assessed the effect of synbiotics on the clinical 
course of extended liver resection for bile duct malignancy. The Intestinal 
microflora and liver function can interact in many different ways, a 
connection called gut–liver axis.58,59 To study this axis, the impact of 
synbiotics on the clinical course of extended liver resection for bile duct 
carcinoma was evaluated. Twenty-one patients received enteral nutrition 
plus a synbiotic combination of 108 Bifidobacterium breve Yakult und L. 
casei Shirota (Yacult BL Seichoyaku, Japan) as well as galacto-
oligosaccharides postoperatively for 14 days. In the synbiotics group, 
19% had bacterial infections compared to 52% in the group without 
synbiotics. 
 A significant reduction of pathogenic bacteria and an increase of 
organic acids in the feces were observed. In another study by the same 
group, 81 patients operated for bile duct carcinoma were administered,  
high dose synbiotics either only postoperatively or 14 days preoperatively 
plus postoperatively. Perioperative treatment with synbiotics led to a 
significantly lower bacterial infection rate as compared to only 
postoperative treatment (12.1% versus 30%). An increased activity of 
natural killer cells and a lower concentration of interleukin-6 levels in the 
blood as expression of a stimulation of the immune response and a 
reduction of the systemic inflammatory response were observed. 58,59 
Liver transplantation 
 Preoperative malnutrition, ascites, portal hypertension, transient 
loss of hepatic macrophage function which serves as a filter for Gram 
negative bacteria in the mesenteric circulation, the extended operation 
with potential extensive blood loss and manipulation and edema of the 
bowel, biliary complications, and the immunosuppression are few of the 
numerous risk factors for bacterial translocation, and infection. 51,60,61 
Therefore, sepsis is the most important cause of death in liver transplant 
recipients. A 1-year organ survival was significantly decreased, and the 
hospital stay prolonged for 24 days costing an additional US $159.967 
per patient.  
 Neuheus and colleagues published two studies, Ninety-five 
patients were enrolled in the first study. And received early enteral 
nutrition plus either selective bowel decontamination (SBD, group 1), a 
synbiotic combination with L. plantarum 299 (see before) and inulin as 
prebiotic (group 2), or inulin only (group 3). Bacterial infection rates were 
lower in the synbiotic group than in the other groups; the difference 
between groups 1 and 2 was statistically significant (48% versus 13%). 
Most of these infections were caused by enterogenic bacteria.  
 In a study of 66 liver transplant recipients who received a synbiotic 
combination with four probiotics and prebiotics (Synbiotic 2000) or only 
the prebiotics, only one patient (3%) had a bacterial infection compared 
to 48% in the other group. Additionally, even the duration of antibiotic 
therapy was significantly shorter (0.1 day versus 3.8 days). No severe side 
effects were observed in the studies; especially, no infections caused by 
the probiotics. 61. 
  
  
 
 
 
MATERIALS AND METHODS 
  
MATERIALS & METHODS 
Study Design and Setting 
 At the Institute of Surgical Gastroenterology & Liver 
Transplantation, Govt. Stanley Medical College, Chennai, India a single 
blind prospective randomized placebo controlled clinical trial was 
conducted.  
 Randomization was computer generated using an on-site computer 
system with randomization software. The study was single blind, with the 
patients being blinded for the intervention. The study design was as 
presented in figure 1. The patients were assessed for eligibility using the 
inclusion and exclusion criteria (detailed below), and those who were 
planned for a Frey procedure were randomized. The patients in whom the 
surgery could not be completed were excluded from the study.  
 
 
 
 
 
 
  
Figure 1: Study Design - Algorithm 
 
 
 
Patients 
 All patients who were suffering from chronic pancreatitis and 
scheduled for Frey procedure were included in this prospective 
monocentric single-blind randomized control study. 
Inclusion Criteria: 
• All Adults between the ages of 18 and 75 years with good 
performance status (Karnofsky performance score >80).  
• Patients with Chronic pancreatitis undergoing Frey 
Procedure 
Exclusion criteria:  
• Renal insufficiency defined as Creatinine > 1.1 mg/dl 
• Presence of Intestinal obstruction 
• Patients who underwent emergency surgery 
• Patients with cerebral disorders with a danger of aspiration 
• Any other contraindications for enteral nutrition.  
 
 
Primary study endpoint:  
 Primary study endpoint fixed as the occurrence of postoperative 
infection during the first 30 days after surgery. The diagnosis of bacterial 
infection was based on systemic signs like fever (≥38°C), along with 
specific clinical symptoms of organ specific infection and a positive 
bacterial culture. Sources/sites of infection were specifically defined for 
the purpose of the study, based on international guidelines. Wound 
infections were defined as detection of pus in the wound along with a 
positive bacterial culture.  
 Respiratory infection was defined as fever, cough, dyspnea along 
with a reduced oxygen saturation, typical pulmonary infiltrate on chest x-
ray, and a positive culture from sputum, or bronchoalveolar lavage.  
Peritonitis or intra-abdominal abscess was defined as fever with the 
presence of intra-abdominal pus and positive bacterial cultures from intra-
abdominal smears. Sepsis was characterised as fever, low arterial blood 
pressure, systemic inflammatory response, and positive bacterial blood 
cultures. A diagnosis of Urinary tract infection made in the presence of 
dysuria, leukocyturia, and a positive urine culture with 105 colony 
forming units/mL.  
  
Secondary study endpoints:  
 Secondary outcome measures were mortality, days to the first 
bowel movement after surgery, number of days in intensive care unit, 
total length of hospital stay and the total duration of antibiotic therapy. 
Ethics, Informed Consent, Safety & Registration of Trial 
 The study was conducted in accordance with the principles of the 
Declaration of Helsinki and 'good clinical practice' guidelines.  Approval 
from the Institutional ethics committee was obtained and all patients gave 
a written informed consent before inclusion in the trial. The study drug 
has been used in clinical practice for indications other than those indicated 
in the current study, its long history of usage in healthcare have shown a 
very good safety profile. 
 During administration of the drug both the patient and the nursing 
staff were required to register any potential side effects or adverse events. 
The criterion set to stop the study was withdrawal of patient consent and 
/ or the occurrence of any serious adverse events owing to the 
administration of the drug.  
 As a testimonial to its bonafide nature, the study has been registered 
with Clinical Trials Registry of India, National Institute of Medical 
Statistics, Indian Council of Medical Research, India. CTRI Number: 
CTRI/2013/06/003737 
Treatment program: 
 Patients’ complete medical history and clinical examination, 
analysis of laboratory parameters, and disease-specific further 
examinations are evaluated. Serum albumin and body mass index are 
measured and calculated to evaluate the nutritional status. All patients are 
stratified using the classification of the American Society of 
Anesthesiologists. Patients are then individually randomized using 
randomization software to one of the two study groups.  
Surgical Procedure 
 All patients undergoing chronic pancreatitis for Frey procedure 
were included. In brief, the procedure itself entails a formal laparotomy 
via a bilateral subcostal incision. The Duodenum is kocherised to 
completely mobilize the second part of the duodenum from the Inferior 
vena cava upto to the right border of the aorta. The gastrocolic omentum 
is divided to enter the lesser sac. The gastrocolic trunk is dissected, doubly 
ligated and divided.  
 The head, body and tail of pancreas are dissected and exposed. The 
pancreas is assessed for the presence of head mass and any other 
suspicious lesions. Based on the preoperative imaging or intraoperative 
Ultrasound, the pancreatic duct is localized in the region of the body to 
the left of the splenic vein-superior mesenteric vein confluence. The duct 
is then laid open from tail upto the head. The pancreatic head and uncinate 
process are then cored out, to lay open the duct completely.  
 A roux –en- y limb of jejunum is fashioned and a side to side 
longitudinal pancreatico-jejunostomy is performed using a single layer 
braided/ monofilament suture in continuous or interrupted fashion. The 
abdomen is drained with bilateral flank drains and closed in layers. 
Intraoperative details like operative time, blood loss and any other 
significant intraoperative events are documented. 
Study Groups 
Group A 
 Specific composition of prebiotics and probiotics (synbiotics) { 
Streptococcus faecalis T-110 – 60 million, Clostridium butyricum TO-A 
– 4 million, Bacillus mesentericus TO-A – 2 million, Lactobacillus 
sporogenes – 100 million, Fructo-oligosaccharides was administered 
thrice daily via a feeding tube or orally. The treatment is started 5 days 
preoperatively and continued postoperatively for the first 10 days after 
surgery. 
Group B 
 This group received identical treatment as group A, with the only 
difference being that the patients received only placebo. The contents of 
the placebo were specifically designed to be inert and to look identical to 
the study drug. The smell and taste of the study substances were identical 
too. The persons who know the type of treatment were the nurse and the 
investigating clinician. The patients were completely blinded to the study 
randomization.  
Regimen of Antibiotics and Catheters 
 All patients received a single dose of intravenous Cefuroxime (1.5 
g) at induction as antibiotic prophylaxis. Following which the antibiotic 
was repeated if the procedure lasts more than 6 hours. Antibiotics were 
then started only in cases of bacterial infection. If there was a suspicion 
of infection, patients were initially treated empirically and then 
appropriate culture based antibiotics were started following resistance 
testing of the isolated bacteria. Proton pump inhibitors (Pantoprazole 40 
mg) were routinely give twice daily as part of antiulcer prophylaxis.  
 During the operation, a central venous line was introduced, and a 
urinary catheterization was also done. These catheters were removed as 
soon as possible except in the rare case of serious complications. 
Analyzed Parameters 
 Primary study endpoint was the occurrence of postoperative 
bacterial infection during the first 30 postoperative days after surgery. 
Therefore, the incidence, the type of infections, and type of isolated 
bacteria were specifically recorded. Secondary outcome measures 
included mortality, first bowel movement, length of hospital stay, days in 
intensive care unit, and duration of antibiotic therapy. In addition, side 
effects which could be attributed to the synbiotics were evaluated. 
 The duration of antibiotic therapy was determined by counting the 
number of days for which the patients received antibiotic therapy. The 
single-shot of antibiotic prophylaxis which was administered peri-
operatively was excluded. Total length of hospital stay was defined as the 
period from the day of the operation and to the day of discharge. To rule 
out any likely differences in the intraoperative and postoperative risk 
factors for the development of infections and to avoid a bias in the study, 
the relevant accompanying diseases, alcohol and nicotine use, antibiotic 
therapy 1 month prior to operation, operating time, and number of units 
of blood and blood products which were intraoperatively and 
postoperatively, were analyzed. Also evaluated were the lengths of stay 
in the intensive care unit, the first day of bowel movement after the 
surgery, and the type and duration of antibiotic therapy. 
 Diarrhea, constipation, vomiting, abdominal cramps, or distention 
and other side effects which could be attributed to the drug, were 
monitored daily until discharge. The presence of any other complications 
was also monitored daily. Blood samples were drawn preoperatively and 
on the postoperative days 1, 5, and 10. The following parameters were 
studied: complete blood count, renal function tests, serum electrolytes and 
liver functions tests. Vital parameters in the form of temperature, pulse 
rate, blood pressure and respiratory rate were recorded serially. 
 In the presence of suspected infection, bacterial cultures from 
urine, blood, wound, and intra-abdominal drainages were done. The 
culture specimens were cultivated on agar plates for aerobic and 
anaerobic bacteria. Differentiation of bacteria, and antibiotic sensitivity 
testing was performed by using routine microbiological methods. Results 
of the cultures were reported, and only patients with clinical signs of 
infection along with positive cultures were treated with antibiotics. 
  
Statistical Analysis 
 Statistical analysis was performed using the SPSS software 
(version 16.0. SPSS, Inc., Chicago, IL, USA). The extended chi-square 
test was used to compare specific variables. The Mann-Whitney U test 
and the Kruskal-Wallis test were used for non-parametric analysis of 
continuous distributed variables. P value of < 0.05 was considered 
statistically significant with a power of 80%. 
 The statistical analysis was performed at the Department of 
Biostatistics, Govt. Stanley Medical College, Chennai, India. A power 
analysis was performed to assess the required sample size and to avoid a 
type II error. From previous published literature and from our own data, 
it was assumed that perioperative synbiotics reduced the incidence of 
infectious complications from 50% to 12%. With alpha of 0.05 and power 
at 80%, along with a dropout rate of 10%, the calculated required sample 
size was 35 patients for each of the groups 
  
  
 
 
 
 
RESULTS 
  
RESULTS 
Demographic and Operative Data 
 Four patients (all four in group B) were excluded from the study 
after randomization because Frey procedure was not possible due to the 
presence of active pancreatitis and extensive collaterals channels over the 
pancreas. All the other 75 randomized patients {Group A (n=39) and 
Group B (n=36)} completed the study. The two groups were homogenous 
with regards to demographic data; there were no differences in the age, 
gender, and American Society of Anaesthesiologists classification 
between the 2 groups (Table 1). 
Postoperative Bacterial Infections 
 12.8% of the patients in Group A and 39% of patients in Group B 
had infective complications. Wound infections (n-3), respiratory 
infections (n-2) were observed in patients who were administered 
synbiotic. While in Group B apart from wound infection (n-8) and 
respiratory infection (n-3), urinary tract infection (n-2) and sepsis (n-1) 
were also observed. All infections were treated with antibiotics. This 
difference was statistically significant (P- 0.05). Most of the isolated 
bacteria were gut-derived with a predominance of Klebsiella Pneumonia, 
and E. coli.  
Length of Hospital Stay and Antibiotic Therapy 
 There was no difference in mean operating times in group A(310 ± 
46 min) and group B(321 ± 35 min). There was a blood loss in group A 
(271 ± 127 ml) and group B (258 ± 112 ml); no difference was noted in 
the two groups. There was no difference in the first bowel movement, and 
ICU stay in the two groups. The mean total length of hospital stay was 
shorter in group A (8.4 ± 2.9) as compared to group B (17.9 ± 5.2). The 
duration of antibiotic intake was also shorter in group A (2.4 ± 4.8) as 
compared to group B (10.8 ± 3.3), these differences were statistically 
significant (p<0.05).  
Side Effects of Synbiotics 
 Synbiotic combinations were well tolerated in all patients. 
Laboratory Parameters 
 The mean laboratory values including hemoglobin, total leukocyte 
count, blood urea nitrogen, serum bilirubin and serum albumin on 
postoperative period days one, five, ten, did not differ significantly 
throughout the two groups. 
 
 
  
 
  
 
 
  
 
 
  
 
 
  
  
 
 
 
DISCUSSION 
  
 DISCUSSION 
 
 Ours is the first randomized control trial in South Asia to evaluate 
the efficacy of synbiotics in the reduction of infectious complications in 
patients undergoing pancreatic surgery.  
 Frey procedure was chosen as the target surgery for four important 
reasons. This procedure involves a defunctioned limb of jejunum, hence 
any anastomotic leak will not interfere in patients alimentation. It will 
also avoid skewing of data due to any infective complications due to the 
leaking anastomosis. Frey procedure involves coring out of the head of 
pancreas; hence it involves undergoing major stress on the part of the 
patient, thereby replicating the milieu which would occur during head 
resection procedures like the Whipple procedure. This would allow 
extrapolation of data and results accrued in this study to other pancreatic 
surgery. The final reason why Frey procedure was chosen for this study 
was that, it is a very commonly performed procedure in this part of the 
country where chronic calcific pancreatitis is endemic. Any reduction in 
infectious complications and morbidity in this subset of patients will be 
beneficial to the patient, healthcare sector and to the society in general.  
 
 This study shows that perioperative synbiotic treatment decreased 
the rate of postoperative infectious complications after pancreatic surgery 
without any adverse effect. 
 Patients undergoing pancreatic resection have multiple risk factors 
for bacterial translocation and infection leading to bacterial infection rates 
of upto 61% 3,4 Recent data on overall bacterial infection rates in 
pancreatic surgery range between 30% and 50% despite advanced 
surgical techniques, broad-spectrum antibiotic prophylaxis, and 
treatment. 5,6  Our own data accrued over the past five years, have shown 
the infectious complications rates to be in the range of 50%. In the present 
prospective, randomized, double-blind trial, synbiotic combination 
significantly reduced this incidence of bacterial nosocomial infections to 
12.8%.  
 There were no significant differences between the groups with 
regards to important risk factors for the development of infections like 
advanced age, comorbidities, operative time or a large number of 
intraoperatively and postoperatively transfused blood products. In 
addition, the number of patients with surgical complications was same in 
both groups. Besides reduction of infection rates, these patients had a 
strong tendency towards a shorter hospital stay, and a significantly shorter 
duration of antibiotic therapy, which led to a reduction of the costs.  
 Nomura et al showed that probiotics led to significant reductions in 
infectious complications (23% versus 53%) and median length of hospital 
stay (19 days versus 24 days) following pancreatic surgery. 52  A double 
blind randomized study in patients undergoing pylorus preserving 
pancreaticoduodenectomy from Berlin, concluded that the incidence of 
nosocomial bacterial infections was significantly lower (12.5% versus 
40%), and only mild wound and urinary tract infections occurred in those 
who were administered perioperative probiotics. 49  
 The PROPARTRIA trial conducted in patients with severe 
pancreatitis showed serious adverse events of synbiotics. 55 The rate of 
infectious complications was comparable in both groups (30% versus 
28%), but the mortality rate was higher in the synbiotic group (16% versus 
%). This was the first study which showed, synbiotics are not always 
beneficial. There have been a few criticisms about the PROPARTRIA 
trial. The patients in the Dutch study were on the average 15 years older 
than those patients in the previous pancreatitis studies, and there was a 
higher frequency of biliary pancreatitis which tends to be more severe 
than ethanol-induced pancreatitis. Greater severity of illness and 
Systemic Inflammatory Response Syndrome was suggested by higher 
Imrie scores and C-Reactive Protein levels in the Besselink study, but this 
was offset by lower APACHE II scores and a lower percentage of 
pancreatic necrosis on CT scan compared to the other studies.49,55  
 The Dutch patients received a greater number of probiotic 
organisms (six types of both Lactobacillus and Bifidobacteria at 1010 
CFU/mL (versus one to four types of Lactobacillus alone in the Olah 
studies). Patients were treated with probiotics for a longer period in the 
Besselink study (4 weeks compared to 1 week in the Olah studies), and 
the Dutch researchers were very aggressive with the probiotic/enteral 
nutrition therapy (as evidenced by the fact that feedings were continued 
on pressor agents in some patients). Factors such as older age, under-
resuscitation, hypoperfusion on pressor therapy, and greater disease 
severity may make the risk prohibitive in certain patients.49,54,55 
 Reasons for the adverse outcome of the Dutch study include an 
85% reduction in the blood supply to the mucosa in patient with acute 
pancreatitis, leading to intestinal hypoperfusion.49 It is known that 
intestinal epithelia under metabolic stress perceive commensal bacteria as 
a threat, leading to increased local inflammation. Therefore, the 
combination of severe pancreatitis, organ failure, intestinal 
hypoperfusion, and an increased (probiotic) bacterial load could have lead 
to increased local inflammation, further compromising mucosal blood 
supply. Another cause could be the increased oxygen demand and/or 
accumulation of fermentation products associated with the presence of 
probiotics, which could have lead to a barrier dysfunction within the gut. 
 Studies from Japan investigating the impact of synbiotics on the 
clinical course of extended liver resection have shown a significant 
reduction in bacterial infections (19% vs. 52%). 50,56,57,58 Studies from 
Europe conducted on patients undergoing colorectal and abdominal 
surgery have shown equivocal results.  
 Current evidence suggests that synbiotic treatment is promising in 
maintaining and repairing the gut microbiota and gut environment, it also 
significantly reduces septic complications in patients with severe 
systemic inflammatory response syndrome (SIRS).39,40 Finally, despite 
the promising clinical results with the use of these therapies, the 
mechanisms of action in the gastrointestinal tract remain undefined. 
Further clinical research is necessary to clarify the effectiveness of such 
therapies and define the appropriate conditions for use, before indiscrete 
widespread application of synbiotics in the perioperative setting. 40,48,49  
 With its environmental, social, cultural and dietary distinctiveness, 
it might not be entirely appropriate to extrapolate western data onto the 
south-Asian subset of the population. Furthermore, there are no clinical 
trials from south east Asia, and the effectiveness of synbiotics in this 
population remains to be assessed.63, 64 
  
Limitations of the study: 
 Even though a prospective randomized trial, this study does suffer 
from a few drawbacks. The synbiotic used was a multibacterial 
combination synbiotics; this study did not perform an analysis between 
the varied types of synbiotics and their effect. This would have given a 
true idea as to how efficacious each synbiotic actually is. Although a 
power analysis was done, the sample size is small; this might have led 
inadvertent concealment of differences between the two groups.  
 The lack of infection in the synbiotic group might by the result of 
type I error. The duration of administration of the synbiotics were 
empirical, there is no evidence to suggest if a shorter or a longer duration 
might be beneficial, this needs to be looked at before, guidelines can be 
formulated on the regular usage of synbiotics perioperatively.  Frey 
procedure might be a true representation of pancreatic surgery, but there 
is no data on how synbiotics might affect outcomes after other pancreatic 
operations. 
 Further studies are required to investigate the mechanism of 
synbiotic treatment in combination with changes in intestinal flora and 
organic acid concentration and the associated decrease in postoperative 
infectious complications. A multicenter, prospective randomized trial 
using different synbiotics formulations would be required to answer the 
questions raised in this study. 
  
 
 
 
 
CONCLUSION 
  
CONCLUSIONS 
• In patients undergoing pancreatic surgery for  
 Chronic Pancreatitis  
Synbiotics significantly reduce  
o infective complications 
o hospital stay  
o antibiotic requirement  
Synbiotics did not influence  
o Day to first bowel movement 
o length of ICU stay 
o Peroperative haematological and biochemical parameters 
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ANNEXURES 
  
TO PARTICIPANTS AND CONSENT FORM 
Name of Participant:     
Title: IMPACT OF PERIOPERATIVE ENTERAL SYNBIOTICS IN 
SURGERY FOR CHRONIC PANCREATITIS: A SINGLE BLIND 
PROSPECTIVE RANDOMIZED CONTROL TRIAL 
You are invited to take part in this research study. The information 
in this document is meant to help you decide whether or not to take part. 
Please feel free to ask if you have any queries or concerns. You are being 
asked to participate in this study being conducted in Govt. Stanley 
Medical College Hospital because you satisfy our eligibility criteria  
What is the purpose of research? 
Postoperative infections occur despite the improvements in 
surgical techniques and refinements in perioperative care. The majority 
of the observed infections are caused by bacteria from the gut, which 
translocate (move) from the intestinal lumen into the blood stream. 
Probiotics (harmless living bacteria- normally found in the intestines) are 
able to influence all pathogenic mechanisms of bacterial translocation. 
Prebiotics are nondigestable food constituents that selectively alter 
growth or activity of one or a limited number of bacterial species. 
Therefore, prebiotics and probiotics are potentially useful in prevention 
of bacterial infections. Used in combination, probiotics and prebiotics are 
called synbiotics. While symbiotic combinations are considered to have 
beneficial effects on human health, their clinical value in surgical patients 
remains unclear given a paucity of applicable clinical studies.  
In this study we assess the clinical usefulness of synbiotics in 
patients who undergo hepatic and pancreatic resections with an aim to 
assess a reduction in infective complications. Information obtained from 
this study would be beneficial to other patients with hepatic or pancreatic 
surgeries in the future. We  have obtained permission  from the 
Institutional  Ethics Committee   for conducting this study. 
The study design 
You will be one of the 1 2 0  patients we plan to recruit in this 
study. You will be assigned to either of the two study groups. You will 
be "randomized" into one of the study groups described below. 
Randomization means that you are put into a group by chance. A 
computer program will place you in one of the study groups.  Neither you 
nor your doctor can choose the group you will be in. Which treatment 
group you will be assigned to will be determined purely by chance, which, 
in scientific language, is called “randomization”. Randomization 
improves the scientific quality of research. You will have an equal chance 
of being placed in any group.  
One group of patients will receive the synbiotic medication, while 
the other group of patients will receive placebo. A placebo is an inactive 
or a dummy medication, which is given to increase the scientific validity 
of our study. Moreover, a placebo is needed so that it does not become 
to which group you are being assigned. This method, in scientific terms 
is known as blinding. This is important for unbiased evaluation of the 
study medication. 
Study Procedures 
Complete medical history and clinical examination, analysis of 
laboratory parameters, and disease-specific further examinations are 
done. Patients are then individually randomized using randomization 
software to one of the 2 study groups.  
Surgical Procedure 
All major pancreatic resection surgeries included in the study 
(Whipple procedure, Distal pancreatectomy, Frey procedure). All Hepatic 
resections surgeries are included in the study.  
Study Groups 
Group A 
Specific synbiotic composition of prebiotics and probiotics is 
administered thrice daily via the feeding tube or orally. The treatment 
started 5 days preoperatively and continued during the first 10 days after 
surgery. 
Group B 
Identical treatment as group A, with the only difference being that 
the patients receive only placebo, the contents look identical in both 
groups. The smell and taste of the study substances are identical, too.  
Blood tests will be taken before the surgery and on the first, fifth 
and tenth day postoperatively, apart from routine/indicated disease 
specific blood tests. These tests are essential to monitor your condition, 
and to assess the safety and efficacy of the treatment given to you.  
Possible risks to you 
Since these are harmless bacteria normally found in the intestines, 
there are very few adverse effects. Some of the common adverse effects of 
the drug which will be given to you, include abdominal pain, vomiting 
and bloating.  
In case of injury or a medical problem during this research study 
Your safety is the prime concern of the research. If you are injured 
or have a medical problem as a result of being in this study, you should 
contact one of the people listed at the end of the consent form. You will 
be provided the required care/treatment. 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your 
medical information (personal details, results of physical examinations, 
investigations, and your medical history). By signing  this  document,  you  
will  be  allowing  the  research  team  investigators,  other  study 
personnel, sponsors, institutional ethics committee and any person or 
agency required by law to view your data, if required. The results of 
clinical tests and therapy performed as part of this research may be 
included in your medical record. The information from this study, if 
published in scientific journals or presented at scientific meetings, will 
not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect 
your medical care or your relationship with the investigator or the 
institution. Your doctor will still take care of you and you will not lose 
any benefits to which you are entitled. 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have 
the right to withdraw from this study at any time during the course of the 
study without giving any reasons. Though advisable that you give the 
investigators the reason for withdrawing, it is not mandatory. 
Right to new information 
If the research team gets any new information during this research 
study that may affect your decision to continue participating in the study, 
or may raise some doubts, you will be told about that information. 
 
 
  
PATIENT CONSENT FORM 
IMPACT OF PERIOPERATIVE ENTERAL SYNBIOTICS IN 
SURGERY FOR CHRONIC PANCREATITIS: A SINGLE BLIND 
PROSPECTIVE RANDOMIZED CONTROL TRIAL 
 
Name of the participant:    
Name of the Principal (Co-) Investigator:    
Name of the Institution:  Govt.Stanley Medical College Hospital 
Documentation of the informed consent 
I, … … … … … … …  have read the information in this form (or it has been read 
to me). I was free to ask any questions and they have been answered. I am 
over 18 years of age and, exercising my free power of choice, hereby give 
my consent to be included as a participant in “Impact Of Perioperative 
Enteral Synbiotics In Surgery For Chronic Pancreatitis: A Single 
Blind Prospective Randomized Control Trial”. 
(1)   I have read and understood this consent form and the information 
provided to me.  
(2)   I have had the consent document explained to me. 
(3)   I have been explained about the nature of the study. 
(4)   My rights and responsibilities have been explained to me by the 
investigator. 
(5)   I have been advised about the risks associated with my participation 
in the study. 
(7)   I agree to cooperate with the investigator and I will inform 
him/her immediately if I suffer unusual symptoms. 
(8)  I am aware of the fact that I can opt out of the study at any time 
without having to give any reason and this will not affect my future 
treatment in the hospital. 
(9)  I am also aware that the investigators may terminate my 
participation in the study at any time, for any reason, without my 
consent. 
(10)  I hereby give permission to the investigators to release the 
information obtained from me as result of participation in this study 
to the sponsors, regulatory authorities, Government agencies, and 
ethics committee. I understand that they may inspect my original 
records. 
(11)  My identity will be kept confidential if my data are publicly 
presented. 
(12)  I have had my questions answered to my satisfaction and I have 
decided to be in the research study. 
I am aware, that if I have any questions during this study, I should 
contact at one of the addresses listed above. By signing this consent from, 
I attest that the information given in this document  has  been  clearly  
explained  to  me  and  apparently understood by me. I will be given a 
copy of this consent document. 
  
Name and signature / thumb impression of the participant  
  (Name)    _____(Signature) Date:    
Name and signature of impartial witness (required for illiterate patients): 
______________(Name)     (Signature) Date:    
Name and signature of the Investigator or his representative obtaining 
consent: 
 _________(Name)   ____________(Signature) Date:  
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1 Anitha 14 F Drug 
Pancr
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Frey 
Procedur
e 
21
.9 I No 300 300 2 3 8  no      
2 Govindasamy 40 M 
Plac
ebo 
Pancr
eas CCP 
Frey 
Procedur
e 
25
.3 I No 300 300 5 4 9  no      
3 Ganesan 32 M Drug 
Pancr
eas CCP 
Frey 
Procedur
e 23 I No 240 400 3 3 7  no      
4 Megalavathy 18 F 
Plac
ebo 
Pancr
eas CCP 
Frey 
Procedur
e 
24
.2 I No 300 250 4 4 10  no      
5 Srinivasan 40 M Drug 
Pancr
eas CCP 
Frey 
Procedur
e 23 I No 300 400 4 4 12  no      
6 Janakiammal 55 F 
Plac
ebo 
Pancr
eas CCP 
Frey 
Procedur
e 29 III No 180 50 5 3 16 10 yes yes     
7 Sivakumar 32 M 
Plac
ebo 
Pancr
eas CCP 
Frey 
Procedur
e 21 I Yes 240 250 4 3 16 7 yes yes     
8 Manikandan 13 M Drug 
Pancr
eas CCP 
Frey 
Procedur
e 22 I No 300 200 4 4 10  yes yes     
9 Raja 18 M Drug 
Pancr
eas CCP 
Frey 
Procedur
e 18 I No 360 600 8 3 20 3 yes   yes   
1
0 
Sanasipandia
n 20 M Drug 
Pancr
eas CCP 
Frey 
Procedur
e 23 I No 195 100 3 3 9  no      
1
1 Sekar 59 M Drug 
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Procedur
e 24 II No 180 150 4 4 15 5 yes   Yes   
1
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eas CCP 
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3 
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Frey 
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e 24 I No 450 500 7 3 16 7 yes   yes   
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2
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3
0 Natrajan 70 M Drug 
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eas CCP 
Frey 
Procedur
e 18 III no 420 500 5 3 12  no      
3
1 Guruswamy 68 M Drug 
Pancr
eas CCP 
Frey 
Procedur
e 17 II no 360 100 3 4 9  no      
3
2 Chinnu 63 M Drug 
Pancr
eas CCP 
Frey 
Procedur
e 21 II no 300 250 4 4 10  no      
3
3 Neela 47 F Drug 
Pancr
eas CCP 
Frey 
Procedur
e 29 I No 300 250 4 4 10  no      
3
4 Pooja 17 F Drug 
Pancr
eas CCP 
Frey 
Procedur
e 18 I No 300 200 4 3 16  no      
3
5 Babu 48 M Drug 
Panc
eas CCP 
Frey 
Procedur
e 24 II No 240 300 4 3 10  no      
3
6 Anjalai 55 F 
Plac
ebo 
Pancr
eas CCP 
Frey 
Procedur
e 23 II No 300 600 5 3 12  no      
3
7 Kavitha 35 F Drug 
Pancr
eas CCP 
Frey 
Procedur
e 26 II No 270 100 4 3 10  no      
3
8 Bhuneshwari 19 F 
Plac
ebo 
Pancr
eas CCP 
Frey 
Procedur
e 23 I No 195 50 4 3 10  no      
3
9 Vidya 26 F Drug 
Pancr
eas CCP 
Frey 
Procedur
e 29 II No 180 50 4 4 9  no      
4
0 Yogander 30 M Drug 
Pancr
eas CCP 
Frey 
Procedur
e 27 I No 210 100 5 4 10  no      
4
1 Wilson 37 M 
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ebo 
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eas CCP 
Frey 
Procedur
e 21 I No 240 100 4 3 10  no      
4
2 
Leenas 
Joseph 53 M 
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eas CCP 
Frey 
Procedur
e 24 II yes 360 460 8 9 21 14 yes     yes 
4
3 
Rahamathuni
sha 38 F Drug 
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eas CCP 
Frey 
Procedur
e 29 II no 420 100 4 3 9  No      
4
4 Mahalakshmi 30 F Drug 
Pancr
eas CCP 
Frey 
Procedur
e 19 I no 240 150 6 4 12  no      
4
5 Gnanammal 40 F Drug 
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eas CCP 
Frey 
Procedur
e 27 I no 240 150 4 3 10  no      
4
6 Ayeshakani 32 F Drug 
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Frey 
Procedur
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n 51 M Drug 
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Frey 
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8 Kamali 13 F 
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5
4 Jayanthi 40 F 
Plac
ebo 
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Frey 
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e 21 I no 180 50 6 4 10 16 yes   yes   
5
5 Ellaiyammal 45 F Drug 
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Frey 
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5
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6
7 Santhosh 31 M 
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6
8 Velumudali 48 M 
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e 26 I no 240 100 6 3 10  no      
6
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eas CCP 
Frey 
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Frey 
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7
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Frey 
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e 19 I no 240 50 4 3 10  no      
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